KSQ-4279   Click here for help

GtoPdb Ligand ID: 11964

Synonyms: example 143 [WO2020132269A1] | KSQ4279 | USP1-IN-1
Compound class: Synthetic organic
Comment: KSQ-4279 is a first-in-class, allosteric inhibitor of the cysteine protease ubiquitin specific peptidase 1 (USP1), that was developed by KSQ Therapeutics as a novel, orally bioavailable cancer therapeutic. It is proposed as a monotherapy or as an adjunct to PARP inhibitor drugs. Its chemical structure was disclosed at the AACR spring meeting in 2022.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 0
Rotatable bonds 8
Topological polar surface area 96.43
Molecular weight 534.21
XLogP 5.33
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES COc1ncnc(c1c1ncc2c(n1)n(nc2)Cc1ccc(cc1)c1nc(cn1C(C)C)C(F)(F)F)C1CC1
Isomeric SMILES COc1ncnc(C2CC2)c1c1nc2c(cnn2Cc2ccc(cc2)c2nc(cn2C(C)C)C(F)(F)F)cn1
InChI InChI=1S/C27H25F3N8O/c1-15(2)37-13-20(27(28,29)30)35-24(37)18-6-4-16(5-7-18)12-38-25-19(11-34-38)10-31-23(36-25)21-22(17-8-9-17)32-14-33-26(21)39-3/h4-7,10-11,13-15,17H,8-9,12H2,1-3H3
InChI Key KCBWAFJCKVKYHO-UHFFFAOYSA-N
References
1. Brenneman JB, Krall EB, Schlabach M, Wylie AA. (2020)
Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (usp1) inhibitors.
Patent number: WO2020132269A1. Assignee: KSQ Therapeutics, Inc.. Priority date: 20/12/2018. Publication date: 25/06/2020.